DK3055409T3 - Metabolisk optimeret cellekultur - Google Patents

Metabolisk optimeret cellekultur Download PDF

Info

Publication number
DK3055409T3
DK3055409T3 DK14851841.8T DK14851841T DK3055409T3 DK 3055409 T3 DK3055409 T3 DK 3055409T3 DK 14851841 T DK14851841 T DK 14851841T DK 3055409 T3 DK3055409 T3 DK 3055409T3
Authority
DK
Denmark
Prior art keywords
cells
cell culture
cell
lactate
culture
Prior art date
Application number
DK14851841.8T
Other languages
English (en)
Inventor
Shawn Lawrence
Amy Johnson
Ann Kim
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52813657&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3055409(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Application granted granted Critical
Publication of DK3055409T3 publication Critical patent/DK3055409T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/60—Buffer, e.g. pH regulation, osmotic pressure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2511/00—Cells for large scale production

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Peptides Or Proteins (AREA)

Claims (17)

1. En metode til kultivering af celler, der omfatter: (a) kultivering af celler i en første cellekultur; (b) bestemmelse af at en stofskifteændring til laktatforbrug har fundet sted i den første cellekultur, og (c) overførsel af cellerne til en anden cellekultur efter at stofskifteændringen til laktatforbrug i cellerne har fundet sted, hvor laktatkoncentrationen i den anden cellekultur indikerer netto laktatforbrug.
2. Metoden i krav 1, hvor cellerne transficeres med DNA, hvorved en polypeptid af interesse indkodes, inden cellerne i en første cellekultur kultiveres, og omfattende opbevaring af en anden cellekultur under forhold, som tillader manifestation af polypeptiden af interesse, og høstning af polypeptiden af interesse fra den anden cellekultur.
3. Metoden i krav 1 eller 2, hvor stofskifteændring til laktatforbrug er påvist af pH, laktat eller basemålinger i den første cellekultur.
4. Metoden i ethvert af krav 1-3, hvor stofskifteændringen til laktatforbrug påvises, efter at pH stiger i det første cellekulturmedium uden tilsætning af base.
5. Metoden i ethvert af krav 1-4, hvor stofskifteændringen finder sted, når cellerne stammer fra eksponentiel fase eller har nået stationær fase i den første cellekultur.
6. Metoden i ethvert af krav 1-5, hvor stofskifteændringen finder sted, når laktatniveauerne stabiliseres i den første cellekultur
7. Metoden i ethvert af krav 1-6, hvor stofskifteændringen finder sted i den første cellekultur ved eller efter 3 dages cellevækst i den første cellekultur.
8. Metoden i ethvert af krav 1-7, hvor de overførte celler har en indpodningscelletæthed på mellem ca. 0,5 x 106 celler/ml til ca. 3,0 x 106 celler/ml i den anden cellekultur.
9. Metoden i ethvert af krav 1-8, hvor trinnet til bestemmelse af stofskifteændring omfatter: (a) måling af pH i den første cellekultur, (b) tilsætning af base for at opretholde pH over en forudbestemt laveste grænse, (c) bestemmelse af at pH er over den forudbestemte laveste grænse i på hinanden følgende intervaller, og (d) ophør af tilsætning af base, derved bestemmes at stofskifteændringen til laktatforbrug har fundet sted i den første cellekultur.
10. Metoden i ethvert af krav 1-9, hvor den første cellekultur er en inokulum celledannelseskultur.
11. Metoden i ethvert af krav 1-10, hvor den anden cellekultur er en produktionskultur.
12. Metoden i ethvert af krav 1-11, hvor overførsel af celler til en anden cellekultur omfatter overførsel af celler til en produktionsbioreaktor.
13. Metoden i ethvert af krav 2-12, hvor polypeptiden af interesse er udvalgt fra gruppen bestående af et antistof, et antigenbindende protein, og et fusionsprotein.
14. Metoden i ethvert af krav 1-12, hvor en eller flere nukleinsyresekvenser er stabilt integrerede i cellernes cellegenom, og hvor nukleinsyresekvensen indkoder en polypeptid af interesse.
15. Metoden i ethvert af krav 1 eller 3-12, hvor cellerne omfatter en eller flere udtryksvektorer, der indkoder en polypeptid af interesse
16. Metoden i ethvert af krav 14 eller krav 15, hvor polypeptiden af interesse er udvalgt fra gruppen bestående af et antistof, et antigenbindende protein og et fusionsprotein.
17. Metoden i ethvert af krav 1-16, hvor cellerne er udvalgt fra gruppen bestående af CHO, COS, retinal, Vero, CV1, HEK293, 293 EBNA, MSR 293, MDCK, HaK, BHK21, HeLa, HepG2, WI38, MRC 5, Colo25, HB 8065, HL-60, Jurkat, Daudi, A431, CV-1, U937, 3T3, L-celle, C127 celle, SP2/0, NS-O, MMT, PER.C6, murinlymfoid og murinhybridomeceller.
DK14851841.8T 2013-10-11 2014-10-10 Metabolisk optimeret cellekultur DK3055409T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361889815P 2013-10-11 2013-10-11
PCT/US2014/059993 WO2015054554A1 (en) 2013-10-11 2014-10-10 Metabolically optimized cell culture

Publications (1)

Publication Number Publication Date
DK3055409T3 true DK3055409T3 (da) 2018-07-30

Family

ID=52813657

Family Applications (3)

Application Number Title Priority Date Filing Date
DK18161278.9T DK3351620T3 (da) 2013-10-11 2014-10-10 Metabolsk optimeret cellekultur
DK14851841.8T DK3055409T3 (da) 2013-10-11 2014-10-10 Metabolisk optimeret cellekultur
DK20193898.2T DK3812453T3 (da) 2013-10-11 2014-10-10 Metabolisk optimeret cellkultur

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK18161278.9T DK3351620T3 (da) 2013-10-11 2014-10-10 Metabolsk optimeret cellekultur

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK20193898.2T DK3812453T3 (da) 2013-10-11 2014-10-10 Metabolisk optimeret cellkultur

Country Status (17)

Country Link
US (2) US20160244725A1 (da)
EP (3) EP3351620B1 (da)
JP (3) JP6663854B2 (da)
KR (4) KR102243980B1 (da)
CN (2) CN105637085A (da)
AU (2) AU2014331776B2 (da)
CA (1) CA2926049C (da)
DK (3) DK3351620T3 (da)
EA (2) EA033783B1 (da)
ES (2) ES2833471T3 (da)
HU (2) HUE039551T2 (da)
IL (2) IL244511A0 (da)
MX (2) MX384960B (da)
PL (2) PL3351620T3 (da)
SG (2) SG10201800772TA (da)
WO (1) WO2015054554A1 (da)
ZA (1) ZA201601550B (da)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11390663B2 (en) 2013-10-11 2022-07-19 Regeneron Pharmaceuticals, Inc. Metabolically optimized cell culture
US20160244726A1 (en) * 2013-10-11 2016-08-25 Regeneron Pharmaceuticals, Inc. Metabolically optimized cell culture
KR102243980B1 (ko) 2013-10-11 2021-04-26 리제너론 파마슈티칼스 인코포레이티드 대사적으로 최적화된 세포 배양
JP7260018B2 (ja) * 2017-03-31 2023-04-18 株式会社三洋物産 遊技機
JP7260011B2 (ja) * 2017-03-31 2023-04-18 株式会社三洋物産 遊技機
JP7260020B2 (ja) * 2017-03-31 2023-04-18 株式会社三洋物産 遊技機
JP7260012B2 (ja) * 2017-04-27 2023-04-18 株式会社三洋物産 遊技機
JP7260013B2 (ja) * 2017-04-27 2023-04-18 株式会社三洋物産 遊技機
JP7310945B2 (ja) * 2017-04-27 2023-07-19 株式会社三洋物産 遊技機
JP7260009B2 (ja) * 2017-04-27 2023-04-18 株式会社三洋物産 遊技機
JP7310947B2 (ja) * 2017-04-27 2023-07-19 株式会社三洋物産 遊技機
JP7272480B2 (ja) * 2017-04-27 2023-05-12 株式会社三洋物産 遊技機
JP7310952B2 (ja) * 2017-04-27 2023-07-19 株式会社三洋物産 遊技機
JP7260021B2 (ja) * 2017-04-27 2023-04-18 株式会社三洋物産 遊技機
US11609120B2 (en) 2017-10-06 2023-03-21 Lonza Ltd Automated control of cell culture using Raman spectroscopy
EP4039786A1 (en) 2017-10-16 2022-08-10 Regeneron Pharmaceuticals, Inc. Perfusion bioreactor and related methods of use
US20200385673A1 (en) * 2017-11-30 2020-12-10 Hoffmann-La Roche Inc. Process for culturing mammalian cells
JP2021519073A (ja) * 2018-03-29 2021-08-10 ジェネンテック， インコーポレイテッド 哺乳動物細胞におけるラクトジェニック活性の制御
GB201810772D0 (en) 2018-06-29 2018-08-15 Ge Healthcare Bio Sciences Ab Method in bioprocess purification system
JP7231355B2 (ja) * 2018-08-22 2023-03-01 日機装株式会社 細胞培養方法および細胞培養装置
CN119264211A (zh) 2018-08-27 2025-01-07 瑞泽恩制药公司 拉曼光谱在下游纯化中的应用
WO2020084034A1 (en) 2018-10-26 2020-04-30 F. Hoffmann-La Roche Ag Multispecific antibody screening method using recombinase mediated cassette exchange
JP2020151560A (ja) * 2020-06-24 2020-09-24 株式会社三洋物産 遊技機
JP2020151559A (ja) * 2020-06-24 2020-09-24 株式会社三洋物産 遊技機
EP3985097A1 (en) * 2020-10-14 2022-04-20 Sartorius Stedim Biotech GmbH A method and system for configuring and/or setup of a downstream process for processing a biomass

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
KR970029803A (ko) 1995-11-03 1997-06-26 김광호 반도체 메모리장치의 프리차지 회로
US6165741A (en) 1997-05-30 2000-12-26 The Trustees Of The University Of Pennsylvania Method for rapid detection of bacterial growth in cultures
US5972650A (en) 1997-06-26 1999-10-26 Brigham And Women's Hospital Tetracycline repressor regulated mammalian cell transcription and viral replication switch
US6919183B2 (en) 2001-01-16 2005-07-19 Regeneron Pharmaceuticals, Inc. Isolating cells expressing secreted proteins
US6953692B2 (en) * 2001-12-18 2005-10-11 Bayer Pharmaceuticals Corporation Device and method for seed-train expansion of mammalian cells
CA2417689C (en) 2002-03-05 2006-05-09 F. Hoffmann-La Roche Ag Improved methods for growing mammalian cells in vitro
US7039770B1 (en) 2002-03-05 2006-05-02 Juniper Networks, Inc. Low latency request dispatcher
US8673589B2 (en) 2002-05-29 2014-03-18 Regeneron Pharmaceuticals, Inc. Inducible eukaryotic expression system
EP1623019B2 (en) 2003-05-15 2017-01-25 Wyeth LLC Restricted glucose feed for animal cell culture
US7531327B2 (en) * 2004-07-23 2009-05-12 Immunomedics, Inc. Methods and compositions for increasing longevity and protein yield from a cell culture
US7335491B2 (en) 2004-08-27 2008-02-26 Wyeth Research Ireland Limited Production of anti-abeta
TWI364458B (en) * 2004-08-27 2012-05-21 Wyeth Res Ireland Ltd Production of tnfr-lg
CN101300342A (zh) * 2005-11-02 2008-11-05 惠氏公司 用于使哺乳动物细胞具备适应性的方法
CA2631184A1 (en) 2005-11-28 2007-05-31 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
US7575890B2 (en) 2006-01-18 2009-08-18 Oxygen Enterprises, Ltd. Method for rapid detection and evaluation of cultured cell growth
ES2541546T3 (es) 2006-11-03 2015-07-21 Wyeth Llc Sustancias que inhiben la glucólisis en cultivo celular
EP2150617B1 (en) 2007-06-04 2014-10-22 Regeneron Pharmaceuticals, Inc. Enhanced expression and stability regions
ES2657055T3 (es) 2007-08-09 2018-03-01 Wyeth Llc Uso de perfusión para mejorar la producción de un cultivo de células alimentado por lotes en biorreactores
US20090325287A1 (en) * 2008-06-13 2009-12-31 Haimanti Dorai Methods for Obtaining High Viable Cell Density in Mammalian Cell Culture
US8470552B2 (en) 2009-10-12 2013-06-25 Keck Graduate Institute Strategy to reduce lactic acid production and control PH in animal cell culture
CA2797356C (en) * 2010-04-26 2020-12-29 Novartis Ag Improved cell culture medium
CA2800728C (en) * 2010-05-28 2020-10-27 Genentech, Inc. Decreasing lactate level and increasing polypeptide production by downregulating the expression of lactate dehydrogenase and pyruvate dehydrogenase kinase
TWI637057B (zh) 2012-11-09 2018-10-01 拜爾沙納有限公司 具交替生物反應器用途之不連續進料批次製程
US20150353542A1 (en) * 2013-01-14 2015-12-10 Amgen Inc. Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture
KR102243980B1 (ko) 2013-10-11 2021-04-26 리제너론 파마슈티칼스 인코포레이티드 대사적으로 최적화된 세포 배양

Also Published As

Publication number Publication date
EP3812453A1 (en) 2021-04-28
JP2016532457A (ja) 2016-10-20
SG11201601681QA (en) 2016-04-28
KR20210046835A (ko) 2021-04-28
WO2015054554A1 (en) 2015-04-16
PL3351620T3 (pl) 2021-03-08
ZA201601550B (en) 2023-05-31
DK3351620T3 (da) 2020-10-26
CN114717196A (zh) 2022-07-08
JP6663854B2 (ja) 2020-03-13
CN105637085A (zh) 2016-06-01
ES2833471T3 (es) 2021-06-15
IL262833A (en) 2018-12-31
HK1253275A1 (en) 2019-06-14
JP6967620B2 (ja) 2021-11-17
MX384960B (es) 2025-03-14
JP2020072760A (ja) 2020-05-14
CA2926049C (en) 2023-09-05
KR20230038324A (ko) 2023-03-17
KR20220020415A (ko) 2022-02-18
SG10201800772TA (en) 2018-03-28
EP3812453B1 (en) 2026-03-25
KR20160062032A (ko) 2016-06-01
EP3351620A1 (en) 2018-07-25
EP3351620B1 (en) 2020-09-02
AU2021200193A1 (en) 2021-03-18
HUE039551T2 (hu) 2019-01-28
US20160244725A1 (en) 2016-08-25
CA2926049A1 (en) 2015-04-16
US20210087535A1 (en) 2021-03-25
IL244511A0 (en) 2016-04-21
JP2022009453A (ja) 2022-01-14
EA201690600A1 (ru) 2016-09-30
KR102358807B1 (ko) 2022-02-08
AU2014331776B2 (en) 2020-10-22
ES2678945T3 (es) 2018-08-21
EA033783B1 (ru) 2019-11-25
HK1223122A1 (en) 2017-07-21
EP3055409A1 (en) 2016-08-17
EP3055409B1 (en) 2018-04-25
JP7377243B2 (ja) 2023-11-09
KR102243980B1 (ko) 2021-04-26
EP3055409A4 (en) 2016-09-28
AU2021200193B2 (en) 2023-08-24
MX2020011334A (es) 2021-07-30
KR102610425B1 (ko) 2023-12-06
DK3812453T3 (da) 2026-04-13
EA201991976A1 (ru) 2020-04-02
MX376623B (es) 2025-03-07
HUE051049T2 (hu) 2021-01-28
MX2016004564A (es) 2016-07-12
AU2014331776A1 (en) 2016-03-24
PL3055409T3 (pl) 2018-10-31
KR102510238B1 (ko) 2023-03-16

Similar Documents

Publication Publication Date Title
AU2021200193B2 (en) Metabolically optimized cell culture
US12545717B2 (en) Metabolically optimized cell culture
US20160244726A1 (en) Metabolically optimized cell culture
HK40042432A (en) Metabolically optimized cell culture
HK1253275B (en) Metabolically optimized cell culture
HK1223122B (en) Metabolically optimized cell culture
EA045030B1 (ru) Метаболически оптимизированная клеточная культура
EA040764B1 (ru) Метаболически оптимизированная клеточная культура
BR122024020669A2 (pt) Método para cultivar células, e, célula hospedeira metabolicamente alterada
BR122024020665A2 (pt) Método para cultivar células, e, célula hospedeira metabolicamente alterada
BR112016007739B1 (pt) Método para cultivar células